Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Khan Shirani

Undersea and Hyperbaric Medicine San Antonio, TX Medical Doctor

NPI 1518135904 CMS profile 520163

414 Navarro St Ste 500, San Antonio, TX 78205

Open in the dashboard

General payments

$953

39 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Khan Shirani of San Antonio, TX is reported in the CMS Open Payments database as having received $953 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $356 7
2024 General $111 4
2023 General $136 7
2022 General $202 12
2021 General $25 2
2020 General $111 6
2019 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Khan Shirani
  • Undersea and Hyperbaric Medicine median
  • Middle half of Undersea and Hyperbaric Medicine
  • National median

In program year 2025, general payments to Khan Shirani were reported at $356. Among 65 Undersea and Hyperbaric Medicine profiles paid that year, the median was $153 and the middle half received between $68 and $340.

Show as a table
Year Khan Shirani Undersea and Hyperbaric Medicine median Middle half National median
2019 $12 $162 $85–$376 $163
2020 $111 $111 $46–$307 $114
2021 $25 $154 $50–$306 $132
2022 $202 $122 $40–$378 $149
2023 $136 $145 $52–$410 $160
2024 $111 $146 $80–$316 $164
2025 $356 $153 $68–$340 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $242 14 payments
  2. Kerecis Limited $167 2 payments
  3. Phathom Pharmaceuticals, Inc. $125 1 payment
  4. Organogenesis Inc. $119 4 payments
  5. Smith+Nephew, Inc. $46 3 payments
  6. Acera Surgical, Inc. $34 2 payments
  7. KCI USA, Inc $25 1 payment
  8. Melinta Therapeutics, Inc. $25 1 payment
  9. Paratek Pharmaceuticals, Inc. $24 1 payment
  10. Next Science LLC $23 1 payment
  11. Other $123 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $953 39 payments
Products named General payments · program years 2019–2025
  1. DALVANCE $213 12 payments
  2. Kerecis SurgiClose Wound Care $150 1 payment
  3. Kerecis SurgiClose Wound Care $150 1 payment
  4. Kerecis SurgiClose Wound Care $150 1 payment
  5. Kerecis GraftGuide $150 1 payment
  6. Kerecis SurgiClose Wound Care $150 1 payment
  7. VOQUEZNA $125 1 payment
  8. TEFLARO $86 5 payments
  9. Puraply $55 3 payments
  10. COLLAGENASE SANTYL $33 2 payments
  11. Other $426 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

88

Median for Preventive Medicine: 100

Drug cost

$1,547

Median for Preventive Medicine: $5,055

Branded share of claims

17%

Median for Preventive Medicine: 27.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gentamicin Sulfate Generic 13 $665
Ssd Silver Sulfadiazine Brand 15 $408
Mupirocin Generic 34 $269
Ciprofloxacin Hcl Generic 11 $125
Triamcinolone Acetonide Generic 15 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 584 Part D prescribers listed as Preventive Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$42,386

Medicare's payments for the services billed

Medicare patients

127

Average age 73

Services billed

594

68 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 66%
Chronic kidney disease 57%
Arthritis 55%
Ischemic heart disease 46%
Heart failure 38%
Depression 33%
Atrial fibrillation 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $19
$19 — —
TEFLARO
  • AbbVie, Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Undersea and Hyperbaric Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record